Physician profile
Mohammed Merchant
NPI 1639130230
$8,004.55
in general payments reported to CMS, 2019-2025
45 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $356 · 2021: $733 · 2022: $1,333 · 2023: $1,907 · 2024: $1,307 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,229 · Education: $8.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,229.33 |
| Education | $8.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,230.81 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,157.43 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $996.14 | 2019-2025 | |
| Abbvie INC. | $860.13 | 2021-2025 | |
| Lilly USA, LLC | $668.26 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $415.56 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $355.83 | 2021-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $284.52 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $202.52 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $185.76 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Vapotherm INC | $178.89 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $174.41 | 2022 | |
| Merck Sharp & Dohme LLC | $153.42 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Lucid Diagnostics INC. | $79.34 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $76.95 | 2020-2025 | Zoryve |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Merchant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.